New combo therapy aims to boost liver cancer survival

NCT ID NCT06999694

Recruiting now Disease control Sponsor: Chang Gung Memorial Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This phase 2 trial tests a new combination treatment for people with advanced liver cancer that cannot be removed by surgery. It combines precise proton radiation with two immunotherapy drugs, tremelimumab and durvalumab. The goal is to see if this approach is safe and works better than current treatments. About 45 participants will be enrolled.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton radiotherapy, tremelimumab, and durvalumab
What this could lead to: If successful, this combination could offer a more effective treatment option for advanced liver cancer, potentially improving survival and tumor control.
What could go wrong: This is an early phase 2 trial with only 45 participants, so results may not apply to everyone. Side effects from the drugs and radiation can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DURVALUMAB are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DURVALUMAB HCC - HEPATOCELLULAR CARCINOMA PROTON RADIOTHERAPY TREMELIMUMAB

Contacts and locations

Locations

Chang Gung Memorial Hospital at Linkou
RECRUITING

Taoyuan City, Taiwan, 333, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.